ICON Public Limited Company
ICLR
Classement en actions
#1607
ICON Public Limited Company, a clinical research organization, provides... ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Prix de l'action
$174.32
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$13.45B
Changement (1 jour)
3.68%
Changement (1 an)
-9.80%
Pays
IE
Échange ICON Public Limited Company (ICLR)
Catégorie
Healthcare
Ratio P/E pour ICON Public Limited Company (ICLR)
Ratio P/E au October 2026 TTM : 39.38
Selon les derniers rapports financiers et le cours de l'action de ICON Public Limited Company, le ratio P/E actuel (TTM) est de 39.38. À la fin de l’année 2023, le P/E de l’entreprise était de 37.95.
Historique du ratio P/E pour ICON Public Limited Company de 2001 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 39.38 | 80.24% |
| 2024 | 21.85 | -42.42% |
| 2023 | 37.95 | 21.09% |
| 2022 | 31.34 | -76.90% |
| 2021 | 135.68 | 331.54% |
| 2020 | 31.44 | 26.76% |
| 2019 | 24.80 | 14.51% |
| 2018 | 21.66 | -1.60% |
| 2017 | 22.01 | 38.92% |
| 2016 | 15.85 | -16.84% |
| 2015 | 19.06 | 4.81% |
| 2014 | 18.18 | -24.06% |
| 2013 | 23.94 | -20.29% |
| 2012 | 30.04 | -33.47% |
| 2011 | 45.15 | 200.61% |
| 2010 | 15.02 | 11.16% |
| 2009 | 13.51 | -7.96% |
| 2008 | 14.68 | -7.47% |
| 2007 | 15.87 | 13.86% |
| 2006 | 13.93 | -38.57% |
| 2005 | 22.68 | 356.33% |
| 2004 | 4.97 | 12.27% |
| 2003 | 4.43 | -18.73% |
| 2002 | 5.45 | -20.05% |
| 2001 | 6.81 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 36.15 | -8.20% |
US
|
|
| 39.77 | 0.99% |
US
|
|
| -290.26 | -837.01% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -13.20% |
US
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.